Dr. Matovu, the investigator of the vaginal ring
Dr Matovu supervised the research site that discovered that the vaginal ring can work Read more>>>>>>>
Dr. Flavia Kiweewa
Uganda Set to Revolutionize HIV Prevention with Lenacapavir and New PrEP Options
Uganda is set to take significant strides in the global fight against HIV, as the Ministry of Health (MOH) sets its sights on integrating new, cutting-edge prevention methods into the country’s National HIV Combination Prevention Strategy. With the aim of…
New Era in HIV Prevention: Uganda Embraces Innovative Technologies
The Uganda Ministry of Health has taken a significant step towards ending AIDS as a public health threat by 2030, embracing cutting-edge innovations in HIV prevention. Despite making progress in combating HIV, with an HIV prevalence of 5.5% among adults…
Government to stock Private Pharmacies with Anti-HIV Drug
“We have seen that people can successfully pick their ARVs from these private pharmacies. So, we think it will be the same with PrEP options,” Kadama said. Read more >>>>>
A New Dawn: World anticipates Gilead’s Lenacapavir Rollout
Uganda is poised to adopt Lenacapavir, a groundbreaking HIV prevention method, following promising results from Gilead Sciences’ PURPOSE 1 trial. The trial, conducted in Uganda and South Africa, demonstrated 100% effectiveness in preventing HIV transmission among women and adolescent girls.…
Injectable HIV drug trial returns promising results
Lenacapavir, which is administered twice yearly, was subjected to a phase three trial in which 5,300 girls and young women aged 16-25 in Uganda and South Africa participated Read more >>>>>>>>>>>>>>>
Ugandan scientists welcome twice-yearly injection against HIV
After over a decade of working on HIV PrEP trials, it’s extremely fulfilling to get such amazing results from the PURPOSE1 study,” said Dr Flavia Matovu Kiweewa. Read more >>>>>>
HIV Prevention breakthrough sparks calls for affordability
First Ugandan Injected with HIV Prevention Drug as General Roll out Starts
The Health Ministry has announced the administration of the first dose of the HIV prevention drug Cabotegravir (Cab-LA) as part of the country’s rollout of long-acting HIV prevention options. Read more >>>>
Purpose 1 Study: First Phase 3 HIV Prevention Trail to Show Zero Infections
Twice-Yearly Lenacapavir or Daily Oral Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study Read more >>>>https://www.busogahealthforum.org/download/purpose-1-study-first-phase-3-hiv-prevention-trail-to-show-zero-infections/?wpdmdl=2889&refresh=67307eb1d4b1c1731231409